A carregar...
Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era
BACKGROUND: In response to the critical shortage of Doxil(®), the US Food and Drug Administration (FDA) allowed temporary importation of non-FDA-approved second-generation liposomal doxorubicin, Lipo-Dox(®). Lipo-Dox utilizes a different liposomal particle than Doxil and demonstrates different pharm...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4133030/ https://ncbi.nlm.nih.gov/pubmed/25143745 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S62881 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|